Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.
The research, published in the October issue of the journal Clinical Cancer Research, provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone.
The study, in women with mutations to BRCA genes – which increase the risk that ovarian cancer will relapse after treatment, as well as being linked to breast and other cancers – showed that ovarian cancers that have become resistant to PARP inhibitors often remain sensitive to conventional chemotherapy.
The study was led by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and looked at follow-up data from patients who had previously taken part in clinical trials sponsored by pharmaceutical company AstraZeneca. The research was supported by grants from the Experimental Cancer Medicine Centre and a range of institutions including Cancer Research UK, the National Institute for Health Research and the Wellcome Trust.
The researchers monitored 89 patients with BRCA-mutated ovarian cancer at The Royal Marsden and other hospitals in the UK, Australia, Belgium, Israel and North America, all of whom received chemotherapy following the development of resistance to a PARP inhibitor called olaparib.
Almost half (49 per cent) of olaparib-resistant patients showed a significant decrease in the size of their tumours when subsequently treated with platinum-based chemotherapy, a frequently-used treatment in ovarian cancer. The results show that a significant proportion of women with ovarian cancer could live longer if they received both treatments.
PARP inhibitors have the advantage of causing fewer and less toxic side-effects than traditional chemotherapy. They are being developed in clinical trials worldwide as a potential 'personalised' treatment for women with BRCA gene mutations, although some have also shown some benefit in patients with non-BRCA tumours.
The researchers also used high-tech new sequencing techniques to probe the precise genetic mechanisms responsible for drug resistance in ovarian tumours. Previously, tumours were thought to evolve resistance to both PARP inhibitors and platinum chemotherapy by acquiring new, secondary mutations to BRCA genes – transforming BRCA proteins from mutated, non-functioning forms back into working proteins.
However, in a small subset of six cases, the study found no sign of secondary BRCA mutations, suggesting that at least in these cases, cancer was developing resistance to PARP inhibitors and platinum-based chemotherapy in different ways.
Study leader Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology at The Institute of Cancer Research, and Consultant at the Royal Marsden, said:
"Our study finds that for many women with ovarian cancer, it is not a case of either/or chemotherapy or PARP inhibitors – there is a good chance that they may respond to both. Although some scientists were concerned that using PARP inhibitors would prevent chemotherapy from being effective, we've resolved that concern by showing that both drug types can work in the same patients.
"Ovarian cancer is a difficult disease to treat and our research does underline the complexity of cancer, and the many different routes it can use to become resistant to treatment. But it also presents us with an opportunity, by showing us that two different types of drug treatment given in sequence could potentially extend lives."
Explore further: 'Cell' article reveals new resistance mechanism to chemotherapy in breast and ovarian cancer
More information: 1. Although BRCA mutations are rare, affecting around one in every 500 women (in the USA), they dramatically increase the risk of developing cancers including breast and ovarian cancer and account for around 15 per cent of ovarian cancer cases. Source: National Cancer Institute factsheet BRCA1 and BRCA2: Cancer Risk and Genetic Testing: accessed online 30 August 2013.
Medical Xpress on facebook
Related Stories
'Cell' article reveals new resistance mechanism to chemotherapy in breast and ovarian cancer
Jun 18, 2013
It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In ...
New cancer drug shows potential in patients with BRCA mutations
Jun 06, 2013
(Medical Xpress)—A new cancer drug designed to be effective in tumours with faulty BRCA genes has generated impressive responses in an early-stage clinical trial.
Renewed hope in a once-abandoned cancer drug class
Jun 19, 2013
Could drugs that block the body's system for repairing damage to the genetic material DNA become a boon to health? As unlikely as it may seem, those compounds are sparking optimism as potential treatments ...
Olaparib shows promise in treating ovarian cancer, even without BRCA mutations
Aug 21, 2011
The PARP inhibitor, olaparib, that has shown promise in women with an inherited mutation in their BRCA1 or BRCA2 gene (accounting for about 5-10% of breast and ovarian cancer cases), has, for the first time, been shown to ...
Experimental drugs for breast cancer could treat lung cancer too
Aug 13, 2013
Cancer Research UK -funded scientists have discovered that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer, reveals research published ...
Recommended for you
Prostate cancer: A change in circulating tumor cells detection has high potential in the prediction
1 minute ago
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen ...
New role for DNA unraveler in preventing brain tumours and other cancers
3 hours ago
(Medical Xpress)—A molecule originally implicated in DNA repair may also be a crucial factor in preventing tumours such as medulloblastoma, a type of childhood brain tumour, according to research published ...
New study changes view about the genetics of leukemia risk
3 hours ago
(Medical Xpress)—A gene that helps keep blood free of cancer is controlled by tiny pieces of RNA, a finding that may lead to better ways to diagnose blood cancers and even lead to new forms of treatment, ...
Steady rise in thyroid cancer not explained by better screening, study says
18 hours ago
(HealthDay)—Better detection alone doesn't explain the dramatic increase in thyroid cancer cases seen in the United States over the past three decades, a new study says.
Breast cancer patients have unrelated plastic surgery after reconstruction
20 hours ago
(HealthDay)—Some breast cancer patients who've had breast reconstruction after mastectomy also undergo cosmetic surgery in an effort to further boost their self-image and self-esteem, according to a new ...
The Cancer Genome Atlas exposes more secrets of lethal brain tumor
23 hours ago
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
User comments
© Medical Xpress 2011-2013, Phys.org network
Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.
The research, published in the October issue of the journal Clinical Cancer Research, provides important evidence that PARP inhibitor drugs and chemotherapy can both be effective in the same patients, helping women live longer than they would if treated with chemotherapy alone.
The study, in women with mutations to BRCA genes – which increase the risk that ovarian cancer will relapse after treatment, as well as being linked to breast and other cancers – showed that ovarian cancers that have become resistant to PARP inhibitors often remain sensitive to conventional chemotherapy.
The study was led by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and looked at follow-up data from patients who had previously taken part in clinical trials sponsored by pharmaceutical company AstraZeneca. The research was supported by grants from the Experimental Cancer Medicine Centre and a range of institutions including Cancer Research UK, the National Institute for Health Research and the Wellcome Trust.
The researchers monitored 89 patients with BRCA-mutated ovarian cancer at The Royal Marsden and other hospitals in the UK, Australia, Belgium, Israel and North America, all of whom received chemotherapy following the development of resistance to a PARP inhibitor called olaparib.
Almost half (49 per cent) of olaparib-resistant patients showed a significant decrease in the size of their tumours when subsequently treated with platinum-based chemotherapy, a frequently-used treatment in ovarian cancer. The results show that a significant proportion of women with ovarian cancer could live longer if they received both treatments.
PARP inhibitors have the advantage of causing fewer and less toxic side-effects than traditional chemotherapy. They are being developed in clinical trials worldwide as a potential 'personalised' treatment for women with BRCA gene mutations, although some have also shown some benefit in patients with non-BRCA tumours.
The researchers also used high-tech new sequencing techniques to probe the precise genetic mechanisms responsible for drug resistance in ovarian tumours. Previously, tumours were thought to evolve resistance to both PARP inhibitors and platinum chemotherapy by acquiring new, secondary mutations to BRCA genes – transforming BRCA proteins from mutated, non-functioning forms back into working proteins.
However, in a small subset of six cases, the study found no sign of secondary BRCA mutations, suggesting that at least in these cases, cancer was developing resistance to PARP inhibitors and platinum-based chemotherapy in different ways.
Study leader Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology at The Institute of Cancer Research, and Consultant at the Royal Marsden, said:
"Our study finds that for many women with ovarian cancer, it is not a case of either/or chemotherapy or PARP inhibitors – there is a good chance that they may respond to both. Although some scientists were concerned that using PARP inhibitors would prevent chemotherapy from being effective, we've resolved that concern by showing that both drug types can work in the same patients.
"Ovarian cancer is a difficult disease to treat and our research does underline the complexity of cancer, and the many different routes it can use to become resistant to treatment. But it also presents us with an opportunity, by showing us that two different types of drug treatment given in sequence could potentially extend lives."
Explore further: 'Cell' article reveals new resistance mechanism to chemotherapy in breast and ovarian cancer
More information: 1. Although BRCA mutations are rare, affecting around one in every 500 women (in the USA), they dramatically increase the risk of developing cancers including breast and ovarian cancer and account for around 15 per cent of ovarian cancer cases. Source: National Cancer Institute factsheet BRCA1 and BRCA2: Cancer Risk and Genetic Testing: accessed online 30 August 2013.
Medical Xpress on facebook
Related Stories
'Cell' article reveals new resistance mechanism to chemotherapy in breast and ovarian cancer
Jun 18, 2013
It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In ...
New cancer drug shows potential in patients with BRCA mutations
Jun 06, 2013
(Medical Xpress)—A new cancer drug designed to be effective in tumours with faulty BRCA genes has generated impressive responses in an early-stage clinical trial.
Renewed hope in a once-abandoned cancer drug class
Jun 19, 2013
Could drugs that block the body's system for repairing damage to the genetic material DNA become a boon to health? As unlikely as it may seem, those compounds are sparking optimism as potential treatments ...
Olaparib shows promise in treating ovarian cancer, even without BRCA mutations
Aug 21, 2011
The PARP inhibitor, olaparib, that has shown promise in women with an inherited mutation in their BRCA1 or BRCA2 gene (accounting for about 5-10% of breast and ovarian cancer cases), has, for the first time, been shown to ...
Experimental drugs for breast cancer could treat lung cancer too
Aug 13, 2013
Cancer Research UK -funded scientists have discovered that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer, reveals research published ...
Recommended for you
Prostate cancer: A change in circulating tumor cells detection has high potential in the prediction
1 minute ago
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen ...
New role for DNA unraveler in preventing brain tumours and other cancers
3 hours ago
(Medical Xpress)—A molecule originally implicated in DNA repair may also be a crucial factor in preventing tumours such as medulloblastoma, a type of childhood brain tumour, according to research published ...
New study changes view about the genetics of leukemia risk
3 hours ago
(Medical Xpress)—A gene that helps keep blood free of cancer is controlled by tiny pieces of RNA, a finding that may lead to better ways to diagnose blood cancers and even lead to new forms of treatment, ...
Steady rise in thyroid cancer not explained by better screening, study says
18 hours ago
(HealthDay)—Better detection alone doesn't explain the dramatic increase in thyroid cancer cases seen in the United States over the past three decades, a new study says.
Breast cancer patients have unrelated plastic surgery after reconstruction
20 hours ago
(HealthDay)—Some breast cancer patients who've had breast reconstruction after mastectomy also undergo cosmetic surgery in an effort to further boost their self-image and self-esteem, according to a new ...
The Cancer Genome Atlas exposes more secrets of lethal brain tumor
23 hours ago
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment